Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00758_DB06228_nanopub.RATd6vhEnc3x0AWcCzIUmooJcCB-I7dDicApkK9ZvDxO0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00758_DB06228 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00758_DB06228 label "DDI between Clopidogrel and Rivaroxaban - Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding. [drugbank_resource:DB00758_DB06228]" assertion.
- drugbank_resource:DB00758_DB06228 identifier "drugbank_resource:DB00758_DB06228" assertion.
- drugbank_resource:DB00758_DB06228 title "DDI between Clopidogrel and Rivaroxaban - Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding." assertion.
- drugbank:DB00758 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00758_DB06228 assertion.
- drugbank:DB06228 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00758_DB06228 assertion.